Wanbury Limited (WANBURY) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.053x

Based on the latest financial reports, Wanbury Limited (WANBURY) has a cash flow conversion efficiency ratio of -0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-56.53 Million ≈ $-611.33K USD) by net assets (Rs1.07 Billion ≈ $11.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Wanbury Limited to measure how much of total assets are equity-financed.

Wanbury Limited - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Wanbury Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Wanbury Limited earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Wanbury Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Wanbury Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Pha Lai Thermal Power JSC
VN:PPC
-0.075x
Grupo Sports World S.A.B. de C.V
MX:SPORTS
0.129x
Firefly AB (publ)
ST:FIRE
0.095x
OncoQuest Pharmaceuticals Inc
KQ:078590
-0.019x
Schloss Wachenheim AG
F:SWA
-0.008x
NIBEC Co. Ltd
KQ:138610
0.024x
Ferronordic AB (publ)
ST:FNM
-0.108x
Comscore Inc
NASDAQ:SCOR
0.016x

Annual Cash Flow Conversion Efficiency for Wanbury Limited (2006–2025)

The table below shows the annual cash flow conversion efficiency of Wanbury Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Wanbury Limited (WANBURY) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs592.72 Million
≈ $6.41 Million
Rs261.02 Million
≈ $2.82 Million
0.440x +209.30%
2024-03-31 Rs279.41 Million
≈ $3.02 Million
Rs39.78 Million
≈ $430.23K
0.142x +123.60%
2023-03-31 Rs-328.16 Million
≈ $-3.55 Million
Rs197.97 Million
≈ $2.14 Million
-0.603x +65.13%
2022-03-31 Rs-234.20 Million
≈ $-2.53 Million
Rs405.23 Million
≈ $4.38 Million
-1.730x -1520.63%
2021-03-31 Rs-1.56 Billion
≈ $-16.90 Million
Rs166.81 Million
≈ $1.80 Million
-0.107x +65.30%
2020-03-31 Rs-1.43 Billion
≈ $-15.51 Million
Rs441.33 Million
≈ $4.77 Million
-0.308x -116.56%
2019-03-31 Rs-2.09 Billion
≈ $-22.63 Million
Rs297.31 Million
≈ $3.22 Million
-0.142x +18.93%
2018-03-31 Rs-1.85 Billion
≈ $-19.97 Million
Rs323.65 Million
≈ $3.50 Million
-0.175x +38.09%
2017-03-31 Rs-1.53 Billion
≈ $-16.58 Million
Rs433.86 Million
≈ $4.69 Million
-0.283x -7.32%
2016-03-31 Rs-1.63 Billion
≈ $-17.65 Million
Rs430.53 Million
≈ $4.66 Million
-0.264x -16.35%
2015-03-31 Rs-1.77 Billion
≈ $-19.16 Million
Rs401.67 Million
≈ $4.34 Million
-0.227x +17.67%
2014-03-31 Rs-1.65 Billion
≈ $-17.85 Million
Rs454.48 Million
≈ $4.92 Million
-0.275x +92.09%
2013-03-31 Rs-212.95 Million
≈ $-2.30 Million
Rs741.21 Million
≈ $8.02 Million
-3.481x -980.07%
2012-03-31 Rs711.13 Million
≈ $7.69 Million
Rs281.25 Million
≈ $3.04 Million
0.395x +747.00%
2011-03-31 Rs1.05 Billion
≈ $11.35 Million
Rs49.02 Million
≈ $530.13K
0.047x -78.40%
2010-03-31 Rs1.92 Billion
≈ $20.81 Million
Rs416.05 Million
≈ $4.50 Million
0.216x -52.49%
2009-03-31 Rs1.58 Billion
≈ $17.13 Million
Rs720.95 Million
≈ $7.80 Million
0.455x +318.55%
2007-03-31 Rs1.29 Billion
≈ $13.96 Million
Rs-268.83 Million
≈ $-2.91 Million
-0.208x -346.01%
2006-03-31 Rs1.01 Billion
≈ $10.94 Million
Rs-47.21 Million
≈ $-510.60K
-0.047x --

About Wanbury Limited

NSE:WANBURY India Drug Manufacturers - Specialty & Generic
Market Cap
$108.14 Million
Rs10.00 Billion INR
Market Cap Rank
#18855 Global
#1022 in India
Share Price
Rs286.20
Change (1 day)
-2.50%
52-Week Range
Rs163.34 - Rs344.75
All Time High
Rs344.75
About

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more